Linked Life Data

17827637

Source:http://linkedlifedata.com/resource/pubmed/id/17827637

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2007-9-10
pubmed:abstractText
Deferasirox is a new tridentate oral iron chelator developed by computer remodeling recently approved by FDA for children above 2 years. Phase II/III trials have demonstrated similar efficacy to desferrioxamine and better chelation efficiency. Adverse events were minor and growth remained unaffected. Data on cardiac iron chelation is limited although some studies have shown it comparable to deferiprone. The benefit to risk profile of deferasirox is favorable. This promising new drug might decrease the burden of subcutaneous or intravenous infusion improving compliance and hence the life expectation in thalassemic patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0974-7559
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
603-7
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Deferasirox: the new oral iron chelator.
pubmed:affiliation
Department of Pediatrics, Maulana Azad Medical College, New Delhi 110 002, India. apdubey52@rediffmail.com
pubmed:publicationType
Journal Article, Review